Chanticleer Holdings Inc

Chanticleer — Merger or Acquisition (November 2019)

19 slides from Chanticleer's merger presentation, Nov 12, 2019

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    § SONNET BioTherapeutics insforwardiooking statements that do notguarantee future perfomance Corporate Presentation November 2019

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se

  3. Slide 3: Corporate Background

    Slide 3: Corporate Background

    Corporate Background Incorporated in New Jersey » Headquarters: Princeton, New Jersey » Other Locations: New York City, Geneva *« Employees, Consultants and Contracted Scientists/Experts: Approximately 30 people * Internal Pipeline Focus: Oncology » Proprietary technology platform » Existing licensi

  4. Slide 4: Corporate Highlights

    Slide 4: Corporate Highlights

    Corporate Highlights Sonnet is a clinicalstage biopharmaceutical company with a proprietary, modular biologic drug development platform We have a deep knowledge of cytokine biology, complemented by extensive drug discovery and development expertise Our corporate strategy comprises an internal therap

  5. Slide 5: The Sonnet Platform

    Slide 5: The Sonnet Platform

    The Sonnet Platform Asset generation capabilities across major biologic drug classes Five Filed Patent Applications: * FyAB design for numerous targets + Immunotherapy o Drug conjugation o Combination with checkpoint inhibitors + Vaccine + Bone Metastasis © CART

  6. Slide 6: The Sonnet Technology Advantage

    Slide 6: The Sonnet Technology Advantage

    The Sonnet Technology Advantage Sonnet’s Fully Human Albumin Binding (F,AB) technology utilizes a single chain antibody fragment (scFv) capable of delivering one or two active drug compounds + Therapeutic payloads attached via flexible linker peptides Following administration, Sonnet's FyAB- derived

  7. Slide 7: Pipeline Overview

    Slide 7: Pipeline Overview

    Pipeline Overview First wave pipeline will target IL-6, IL-12, IL-15, IL-18, GMcSF and TGFp 8> FyAB Platform Program Indications Chemotherapy Induced SONEO8O lew: close: IL=6} Peripheral Neuropathy” SON-1010 (IL12-F,AB) Undisclosed Solid Tumor SON-1210 (IL15-F,AB-IL12) Undisclosed Solid Tumor SON-20

  8. Slide 8: IL-6: A Disease Modifier of CIPN

    Slide 8: IL-6: A Disease Modifier of CIPN

    IL-6: A Disease Modifier of CIPN In peripheral neurons, IL-6 triggers a series of pathways for the maintenance of mitochondrial function and axonal regeneration. CIPN Patient Population* + >50% of cancer patients receiving chemotherapy develop CIPN + CIPN peak prevalence as high as 70% + New cases u

  9. Slide 9: IL-6 Intrinsically Reactivates Axonal Growth

    Slide 9: IL-6 Intrinsically Reactivates Axonal Growth

    IL-6 Intrinsically Reactivates Axonal Growth IL-6 maintains / restores nerve fiber density IL-6 restores sensation Intraepidermal nerve fibers density * Rats (n = 10/group) 0 rT * Rats (n = 10/group) Taxol (6mg/kg/week, ip.) ca ag * Cisplatin (2mg/kg, i-p.) cars ro a 3° = = RRRREMA? 00 ou oe on oo b

  10. Slide 10: SON-080: Clinical History

    Slide 10: SON-080: Clinical History

    SON-080: Clinical History Low dose recombinant human IL-6 is safe in cancer patients In Phase | studies comprising 214 total cancer patients: SC delivery of IL-6 doses dependently increases plasmatic IL-6, with plasmatic t1/2~ 4 hours Innone of the trials was exacerbation of tumour burden observed I

  11. Slide 11: FHAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life

    Slide 11: FHAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life

    FyAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life The aim of this study was to demonstrate in mice, the pharmacokinetic (pK) behavior of naked IL-12 and IL-15 compared to the same interleukins linked to Sonnet’s F4AB domain Method: 8 mice C57B/ TP, Age 9.5 weeks dose IV, sacrificed @ 5, 15,

  12. Slide 12: anti-TGFβ and anti-TGFβ-FHAB: Evaluating Tumor Accumulation

    Slide 12: anti-TGFβ and anti-TGFβ-FHAB: Evaluating Tumor Accumulation

    anti-TGFg and anti-TGFp-F,AB: Evaluating Tumor Accumulation An in vivo Demonstration of F,AB Proof-of-Concept Western blot analysis of Mouse 4T1 (TGFp-positive) tumor (~150mm®?) extracts from mice terminated at 0.5, 4, 12 and 24-hours post IV injection with 100 ug/mouse of F,AB, anti-TGFp (4D9M) and

  13. Slide 13: IL12-FHAB vs IL-12: Tumor Volume Reduction

    Slide 13: IL12-FHAB vs IL-12: Tumor Volume Reduction

    IL12-F,AB vs IL-12: Tumor Volume Reduction Comparison of Tumor Volumes Between Groups on Day 10 Post Treatment (Day 0 @ 100 mm?) 3000, 1L12 vs 1L12-FyAB . Single Dose E MM GI: Vehicle ee E 2 A MM G2: 112 S00: 2 “Mm G3: ILI2F,AB os 3 $ > 2 , MM Ga L12 108s Bis 2 MM G5: IL12-F,AB 3 = ME Gé: IL12 0 2 4

  14. Slide 14: IL12-FHAB vs IL-12: Survival Data

    Slide 14: IL12-FHAB vs IL-12: Survival Data

    8 IL12-F,AB vs IL-12: Survival Data x o id 604 404 % Animal Survived to 2000mm? Single Dose Median Days for 50% Tumor MM GI: Vehicle each 2o90mm"3 a 10 G2: IL12 @ 12 ‘ G3: anf Sa @ 14 a 12 G4: IL12 5 a 10, * G5: san “se ze ri = a a5 * Gé: IL12 +o, HO _Oae SS ‘* Equal molar IL-12 concentrations Compa

  15. Slide 15: IL12-FHAB vs IL-12: Additional Tumor Reduction Data

    Slide 15: IL12-FHAB vs IL-12: Additional Tumor Reduction Data

    IL12-F,AB vs IL-12: Additional Tumor Reduction Data Evaluation of Single Dose (SD) IL12-F,,AB (1.3ug) vs IL-12 (80ug) in B16F1O Melanoma (established @100 mm3, n=8) =@® Placebo a: 1L12-F, AB} (1.3ug, SD) = Molar I-12 (1pg) and 1L12-F4AB (1.3ug) are molar equivalent and have similar bioactivity, in A

  16. Slide 16: IL15-FHAB-IL12 vs IL12-FHAB

    Slide 16: IL15-FHAB-IL12 vs IL12-FHAB

    IL15-FAB-IL12 vs IL12-F,AB Single I.V. Dose @ 100 mm® SC B16F10 Day 10 Tumor Volume (n=8) 1500 Sonnet Bi-Specific Construct 1L15-F,AB-IL12 Synergistic Biologic Activity: 1000 IL-12: 4 IL-15 alpha receptor, IFN, 500 NK/T cells, THI and | Treg IL-15: 7 IL-12beta I receptor, NK | cells & | CD8 memory l

  17. Slide 17: IL15-FHAB-IL12 vs Concomitant IL-12 and IL-15

    Slide 17: IL15-FHAB-IL12 vs Concomitant IL-12 and IL-15

    IL15-F,,AB-IL12 vs Concomitant IL-12 and IL-15 Day 11 hha. 1L15-F,,AB-IL12 shows better reduction than IL12-F,,AB-IL15 or free, concomitantly dosed IL-12 and IL-15 Day 11 vehicle at +3000m3 not shown HM IL-12 (5g) + IL-15 (ug) ME 1L12-FYAB-IL15 (1.5yg) MMB IL12-FAB-IL15 (6g) (@ 1L15-FYAB-L12 (1.5yg)

  18. Slide 18: Execution Efficiency

    Slide 18: Execution Efficiency

    Execution Efficiency Integrating a Best-in-Class Platform with a World-Class Development Strategy Cell Line - 1L12-F,AB Sartorius 1L15-FyAB-IL12 7 Exploring innovative cho Leadership: Analytics - clinical plans | seed SONNET Bio-oulsource + Latham BioPharm 1L12-FAB IL-6 1L15-F,AB-IL12 Identified CRO

  19. Slide 19: Leadership

    Slide 19: Leadership

    Leadership Accomplished management team with deep experience in biotechnology ©@3 ® Pankaj Mohan, PhD Founder, CEO & Chairman Biotechnology entrepreneur with start up, ceademic, large biopharma and government expevence. Founded Oncobiotogics in 2011 and led it to a successful IPOin 2016 (Nasdag: ONS

Source: SEC EDGAR · 425 filed Nov 12, 2019

More decks from Chanticleer Holdings Inc